Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
Abstract
Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use.
Document Type
Review
Publication Date
8-2-2013
Digital Object Identifier (DOI)
http://dx.doi.org/10.3390/ph6080915
Repository Citation
Wallace, Eric L. and Smyth, Susan S., "Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis" (2013). Gill Heart & Vascular Institute Faculty Publications. 4.
https://uknowledge.uky.edu/heart_facpub/4
Notes/Citation Information
Published in Pharmaceuticals, v. 6, no. 8, p. 915-928.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.